Paul Cacciatore
Paul Cacciatore campaign leader

UK NICE Fails To Support Avastin For Recurrent Advanced Ovarian Cancer

The UK's National Institute for Health and Clinical Excellence (NICE) published draft guidance (http://www.nice.org.uk/newsroom/pressreleases/NICEDraftGuidanceDoesNotRecommendBevacizumabForRecurrentAdvancedOvarianCancer.jsp) today that fails to support the use of bevacizumab (Avastin) for treating recurrent advanced ovarian cancer, which has returned six months or more after initial treatment with platinum-based chemotherapy (i.e., platinum-sensitive disease).

to comment